Figure 1. Suggested pathways for SARS-CoV-2 mediated ACE upregulation and ACE 2 downregulation. Endothelial activation pathways leading to intense pulmonary vasoconstriction in COVID-19: SARS-CoV-2 spike protein binds to ACE 2 on the pulmonary epithelium and causes TACE-mediated shedding of ACE 2 ectodomain resulting in downregulation of ACE 2. Activated TACE causes concomitant shedding of soluble TNF α and IL-6 receptor on the apical, basal and basolateral side of the epithelial cell. TNF α causes increased expression of AT1R on endothelial cells. This results in increased AT II mediated harmful effects and reduced AT 1-7 mediated protective actions. High AT II activity reduces the expression of AMPK, a mediator for balance between ACE and ACE 2. AT II increase the conversion of TACE dimer to TACE monomer (active form) via AT1R/p38 MAPK and AT1R/ERK pathway. Thus, a vicious cycle of ACE/ACE 2 overactivity is established (Mechanistic pathways as shown in Inset). Due to relatively high expression of AT1R on pulmonary endothelium, vasoconstrictive actions of AT1R are only partly counterbalanced by AT2R mediated vasorelaxation. Increased levels ET-1 and peroxynitrite with relatively reduced levels of NO results in intense pulmonary vasoconstriction. (Pathways highlighted green are relatively activated while red highlights represent relative inactivation)
ACE: angiotensin-converting enzyme; ACE 2: angiotensin-converting enzyme 2; AT II: Angiotensin II; AT I: Angiotensin I; AT1R: Ang II type-1 receptor; AT2R: Ang II type-2 receptor; NOX: nicotinamide adenine dinucleotide phosphate oxidase; LOX-1: Lecithin-Like oxLDL Receptor-1; ETAR: Endothelin-1A receptor; B2R: B2 receptor; eNOS: endothelial nitric oxide synthase; SOD: superoxide dismutase; NO: nitric oxide; PLC: phospholipase C; PKC: protein kinase C; TACE: Tumor necrosis factor alpha converting enzyme; s-TNF-α: soluble tumor necrosis factor alpha; IL6R1: interleukin 6 receptor; IL6: interleukin 6; AT 1-7:angiotensin 1-7; PI3K/PKB/Akt: phosphoinositide-3-kinase–protein kinase B/Akt; AMPK: 5’ adenosine monophosphate-activated protein kinase; miR: microRNA; EC: endothelial cell; VSMC: vascular smooth muscle cell.